The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2022 for the Treatment of Uterine Cervical Cancer are revised from the 2017 guideline. This guideline aimed to provide standard care for cervical cancer, indicate appropriate current treatment methods for cervical cancer, minimize variances in treatment methods among institutions, improve disease prognosis and treatment safety, reduce the economic and psychosomatic burden of patients by promoting the performance of appropriate treatment, and enhance mutual understanding between patients and healthcare professionals. The guidelines were prepared through the consensus of the JSGO Guideline Committee, based on a careful review of evidence gathered through the literature searches and the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise seven chapters and 5 algorithms. The main features of the 2022 revision are as follows: 1) added discussed points at the final consensus meeting; 2) revised the treatment methods based on the International Federation of Gynecology and Obstetrics 2018 staging system; 3) examined minimally invasive surgery based on Laparoscopic Approach to Cervical Cancer trial; 4) added clinical question (CQ) for treatments of rare histological types, gastric type, and small-cell neuroendocrine carcinoma; 5) added CQ for intensity-modulated radiation therapy; 6) added CQ for cancer genomic profiling test; and 7) added CQ for cancer survivorship. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2022 for the Treatment of Uterine Cervical Cancer.

中文翻译：

---

日本妇科肿瘤学会 2022 年宫颈肿瘤治疗指南。

日本妇科肿瘤学会 (JSGO) 2022 年宫颈癌治疗指南是对 2017 年指南的修订。本指南旨在为宫颈癌提供规范化护理，指出当前宫颈癌适宜的治疗方法，尽量减少机构之间治疗方法的差异，改善疾病预后和治疗安全性，通过促进适当治疗的实施，减轻患者的经济和心身负担。 ，并增进患者和医疗保健专业人员之间的相互了解。该指南是在认真审查文献检索收集的证据以及日本医疗健康保险制度和实际临床实践情况的基础上，经过JSGO指南委员会的共识而制定的。该指南包括七章和 5 种算法。2022年修订版的主要特点如下： 1）增加了最终共识会议讨论的要点；2）根据国际妇产科联合会2018分期系统修订了治疗方法；3）基于腹腔镜宫颈癌试验的微创手术进行检验；4）增加了罕见组织学类型、胃型和小细胞神经内分泌癌治疗的临床问题（CQ）；5) 调强放射治疗增加了CQ；6) 新增CQ用于癌症基因组图谱测试；7) 增加了癌症生存的 CQ。每项建议都附有基于指南委员会成员达成共识的建议类别分类。在此，我们介绍 JSGO 2022 年宫颈癌治疗指南的英文版。